Table 4.

Patient characteristics of the biomarker population. Correlation between patient characteristics and the mean level of circulating tumor DNA (ctDNA) at baseline determined either by RAS/RAF mutation (Mut ctDNA) or NPY methylation (Meth ctDNA) in the biomarker population, n = number, CI = confidence interval. In 82 patients a baseline plasma sample was available and the correlations are based on these patients.

Characteristic	Categories	Clinical Trial, n	Mut ctDNA			Meth ctDNA
			n	Mean % (95%CI)	p-Value	n	Mean % (95%CI)	p-Value
Age	Median (min–max), years 65 (28–77)	100	46	25 (19–32)	0.19	82	25 (20–30)	0.24
Sex	Female	47	21	25 (14–36)		40	21 (14–27)
	Male	53	25	25 (18–33)	0.77	41	30 (22–37)	0.11
Localization of primary tumor	Right colon	30	18	26 (16–37)		24	30 (19–44)
	Left colon	31	14	27 (12–41)		24	21 (10–31)
	Rectum	35	13	23 (12–35)	0.98	31	23 (17–30)	0.32
Performance status	0	43	22	24 (15–33)		34	21 (15–30)
	1	54	24	27 (17–36)	0.96	46	27 (19–34)	0.58